Rationale and clinical results of multi-target treatments in oncology

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted biological therapy for cancer has significantly evolved over the last decade.
• Early successes involved inhibitors of the ErbB receptor family, such as EGFR and HER-2, utilizing monoclonal antibodies (MAbs) and tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To review the rationale behind multi-targeted therapeutic approaches in cancer treatment.
• To discuss the clinical experience with multi-targeted agents, with a specific focus on those targeting EGFR.

Main Methods:

• Literature review of targeted therapy development and clinical trials.
• Analysis of the strategic development of multi-targeted agents and combination therapies.
• Focus on molecules with anti-EGFR mechanisms of action.

Main Results:

• The development of targeted therapies has progressed from single-pathway inhibitors to multi-targeted agents.
• Recent approvals of multi-targeted TKIs like sorafenib and sunitinib signify a new era in cancer treatment.
• A new wave of multi-targeted compounds is entering clinical trials, raising questions about optimal strategies and drug differentiation.

Conclusions:

• The shift towards multi-targeted therapy acknowledges that tumors often rely on multiple signaling pathways for survival.
• Investigational strategies are exploring the inhibition of multiple pathways or multiple steps within a single pathway.
• Further research is needed to clarify the optimal use and differentiate between the growing number of multi-targeted agents, especially those with anti-EGFR activity.